U.S. Moderna vaccine is also effective for the elderly, the EU plans 80 million doses

Reporter : Yuning / Editor : Changqing / Publisher : Sound Of Hope

Ref : https://www.soundofhope.org/post/415609 

Translation, editing : Gan Yung Chyan, KUCINTA SETIA

The second batch of test results submitted by the American biochemical company Moderna to the Center for Disease Control and Prevention on 26 August 20206 local time showed that the the SARS-CoV-2 vaccine developed by the company is safe and can also stimulate strong immunity in the elderly. The European Union has ordered 80 million doses of this vaccine on 24 August.

According to Politics Weekly, this batch of data from Moderna was collected from 20 55-year-old adults. The results showed that the CCP in their bodies two months after the second injection of the vaccine. Virus (SARS-CoV-2) antibody levels are still higher than those in those who have recovered from covid.

Moderna said that the company has submitted this result for peer review, but has not yet published it in an official scientific journal.

Tal Zaks, the Chief Medical Officer of Moderna, said that the company's first tests on young people, announced in July, had similar results.

Scientists have always been unclear about the efficacy of the currently developed SARS-CoV-2 vaccine for the elderly, because as we age, the ability of the human immune system to resist the threat of invading viruses also declines. A vaccine that works for young people does not necessarily work for older people.

The European Union has pre-ordered 80 million doses of this vaccine on 24 August.

Zachs said the company plans to submit the results of the third batch of tests to the regulatory authorities later this year or early next year to apply for a drug license.